Inactive Instrument
Merrimack Pharmaceuticals Inc Stock Nasdaq
Stocks
US5903281005
Biotechnology & Medical Research
| Market Cap | 224M 196M 180M 166M 313M 21.55B 320M 2.16B 848M 10.55B 840M 822M 36.33B | P/E 2022 |
-100x | P/E 2023 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 205M 179M 165M 152M 287M 19.73B 293M 1.97B 777M 9.66B 769M 753M 33.26B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
98.81% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +8.74% |
| Manager | Title | Age | Since |
|---|---|---|---|
Gary Crocker
CEO | Chief Executive Officer | 74 | 28/06/2019 |
Timothy Surgenor
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Gary Crocker
CHM | Chairman | 74 | 01/01/2005 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +8.74% | -10.76% | - | - | 224M | ||
| -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | ||
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | ||
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | ||
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | ||
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | ||
| +0.46% | -3.49% | - | - | 16.21B | ||
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | ||
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | ||
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | ||
| Average | +0.92% | +0.03% | +65.98% | +98.43% | 27.07B | |
| Weighted average by Cap. | -0.05% | -0.18% | +79.44% | +123.32% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -1.54M -1.35M -1.25M -1.15M -2.16M -149M -2.21M -14.88M -5.85M -72.82M -5.8M -5.67M -251M | -1.18M -1.03M -952K -878K -1.65M -114M -1.69M -11.38M -4.48M -55.7M -4.44M -4.34M -192M |
| Net Debt | -19.44M -16.99M -15.68M -14.45M -27.23M -1.87B -27.84M -187M -73.7M -917M -73M -71.4M -3.16B | -18.88M -16.49M -15.22M -14.03M -26.44M -1.82B -27.03M -182M -71.56M -890M -70.89M -69.33M -3.06B |
Employees
-
















